Expanding Patient Reach: Developing Novel INCB161734 (KRAS G12D Inhibitors) Combinations That Work Across Heterogeneous Tumors
- Combining KRAS inhibitors with orthogonal agents in novel ways to increase the depth and breadth of efficacy in heterogenous tumors
- Reevaluating ways to broaden, not shrink, the treatable KRAS G12D patient population, avoiding combinations that only benefit narrow biomarker defined subsets
- Mutant-selective KRAS inhibitors enable maximal mutant KRAS inhibition while limiting off-tumor to the extent possible off-tumor activity